Aradigm Announces Detailed Third Party Evaluation Results for Apulmiq (FDA)/Linhaliq (EMA)
Aradigm Corporation (OTCQB: ARDM) ("Aradigm" or the "Company") today announced specific, detailed results of an independent third party evaluation (TPE) of the Phase 3 clinical trial results for Apulmiq.
- Aradigm Corporation (OTCQB: ARDM) ("Aradigm" or the "Company") today announced specific, detailed results of an independent third party evaluation (TPE) of the Phase 3 clinical trial results for Apulmiq.
- The TPE results also verify the already reported non-significant primary and secondary PE endpoint results of ORBIT-3.
- A meeting has been scheduled with the FDA to discuss these TPE verified Phase 3 trial results.
- Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.